Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II clinical trial of VP-16-213 in ovarian cancer.

× No keyword cloud information.

7 in total

Review 1. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors: J M Henwood; R N Brogden
Journal: Drugs Date: 1990-03 Impact factor: 9.546

Review 2. Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors: R M Canetta; S K Carter
Journal: J Cancer Res Clin Oncol Date: 1984 Impact factor: 4.553

Review 3. Oral etoposide for the treatment of recurrent ovarian cancer.

Authors: R F Ozols
Journal: Drugs Date: 1999 Impact factor: 9.546

Review 4. The podophyllotoxin derivatives VP16-213 and VM26.

Authors: B F Issell
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

5. Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer.

Authors: Wonkyo Shin; Hye-Joo Lee; Seong J Yang; E Sun Paik; Hyun-Jin Choi; Tae-Joong Kim; Chel Hun Choi; Jeong-Won Lee; Duk-Soo Bae; Byoung-Gie Kim
Journal: Obstet Gynecol Sci Date: 2018-05-09

6. Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer.

Authors: Heeseok Kang; Tae-Joong Kim; Chel Hun Choi; Jeong-Won Lee; Je-Ho Lee; Duk-Soo Bae; Byoung-Gie Kim
Journal: J Korean Med Sci Date: 2009-09-24 Impact factor: 2.153

7. Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer.

Authors: M Baur; E Schernhammer; M Gneist; P Sevelda; P Speiser; M Hudec; Ch Dittrich
Journal: Br J Cancer Date: 2005-03-28 Impact factor: 7.640

7 in total